Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Barts & The London NHS Trust
With
National Health Service, United Kingdom
Age
16–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Medical record diagnosis of asthma
Age ≥ 16 years and ≤ 80 years on day of first dose of IMP
If a woman of child-bearing potential, is sexually abstinent or has negative pregnancy test within 7 days of recruitment and agrees to use reliable form of contraception until she has completed the study
Able to give written informed consent to participate in the study
You may not be if
Diagnosis of COPD
Known sarcoidosis, hyperparathyroidism, nephrolithiasis, active tuberculosis, vitamin D intolerance, liver failure, renal failure, terminal illness, lymphoma or other malignancy not in remission for ≥ 3 years
Any other condition that, in an investigator's judgement, might compromise patient safety or compliance, interfere with evaluation or preclude completion of the study
Taking benzothiadiazine derivative, cardiac glycoside, carbamazepine, phenobarbital, phenytoin or primidone
Taking dietary supplement containing vitamin D up to 2 months before first dose of IMP
Treatment with any investigational medical product or device up to 4 months before first dose of IMP
Breastfeeding, pregnant or planning a pregnancy
Baseline corrected serum calcium \> 2.65 mmol/L
Baseline serum creatinine \> 125 micromol/L
Smoking history \>15 pack-years
Clareo Health | Trial of Vitamin D Supplementation in Asthma
